Mpox 严重程度评分系统的制定与初步应用。
Development and Pilot of an Mpox Severity Scoring System.
机构信息
Division of Infectious Diseases, Vagelos College of Physicians and Surgeons, Columbia University, NewYork, New York.
Division of Infectious Diseases, Weill Cornell Medicine, New York, NY.
出版信息
J Infect Dis. 2024 Mar 26;229(Supplement_2):S229-S233. doi: 10.1093/infdis/jiad492.
Abstract
Clinical severity scores facilitate comparisons to understand risk factors for severe illness. For the 2022 multinational monkeypox clade IIb virus outbreak, we developed a 7-item Mpox Severity Scoring System (MPOX-SSS) with initial variables refined by data availability and parameter correlation. Application of MPOX-SSS to the first 200 patients diagnosed with mpox revealed higher scores in those treated with tecovirimat, presenting >3 days after symptom onset, and with CD4 counts <200 cells/mm3. For individuals evaluated repeatedly, serial scores were concordant with clinical observations. The pilot MPOX-SSS demonstrated good discrimination, distinguished change over time, and identified higher scores in expected groups.
摘要
临床严重程度评分有助于比较，以了解导致严重疾病的风险因素。针对 2022 年多国猴痘 IIb 病毒爆发，我们开发了一个 7 项的猴痘严重程度评分系统（MPOX-SSS），初始变量经过数据可用性和参数相关性的优化。在对 200 名确诊感染猴痘的患者进行应用后发现，接受特考韦瑞治疗、症状出现后超过 3 天、CD4 计数<200 个细胞/mm3 的患者的评分更高。对于反复评估的个体，连续评分与临床观察结果一致。该初步的 MPOX-SSS 显示出良好的判别能力、能区分随时间的变化，并识别出预期的高评分组。
相似文献
1
Development and Pilot of an Mpox Severity Scoring System.Mpox 严重程度评分系统的制定与初步应用。
J Infect Dis. 2024 Mar 26;229(Supplement_2):S229-S233. doi: 10.1093/infdis/jiad492.
2
Effectiveness of Tecovirimat in Mpox Cases: A Systematic Review of Current Evidence.特考韦瑞玛在猴痘病例中的有效性：当前证据的系统评价
J Med Virol. 2024 Dec;96(12):e70122. doi: 10.1002/jmv.70122.
3
Repurposing Drugs for Synergistic Combination Therapies to Counteract Monkeypox Virus Tecovirimat Resistance.重新利用药物进行协同联合治疗以对抗猴痘病毒对特考韦瑞的耐药性。
Viruses. 2025 Jan 13;17(1):92. doi: 10.3390/v17010092.
4
Epidemiology and phylogenomic characterisation of two distinct mpox outbreaks in Kinshasa, DR Congo, involving a new subclade Ia lineage: a retrospective, observational study.刚果民主共和国金沙萨两起不同的猴痘疫情的流行病学和系统基因组特征分析，涉及一个新的Ia亚分支谱系：一项回顾性观察研究
Lancet. 2025 Jul 5;406(10498):63-75. doi: 10.1016/S0140-6736(25)00294-6.
5
Therapeutics for treating mpox in humans.人类天花治疗方法。
Cochrane Database Syst Rev. 2023 Mar 14;3(3):CD015769. doi: 10.1002/14651858.CD015769.
6
Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis.2022 年猴痘疫情期间与疫情前相比，猴痘患者的临床特征和结局：系统评价和荟萃分析。
Rev Med Virol. 2024 Jan;34(1):e2508. doi: 10.1002/rmv.2508.
7
Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.在猴痘疫情期间，为年龄≥18岁有猴痘感染风险人群使用JYNNEOS（天花和猴痘活病毒非复制疫苗）：美国免疫实践咨询委员会的建议，2023年
MMWR Morb Mortal Wkly Rep. 2025 Jun 19;74(22):385-392. doi: 10.15585/mmwr.mm7422a3.
8
Correlation between microneutralization test and a multiplexed immunoassay for evaluation of monkeypox and vaccinia virus antibodies before and after smallpox vaccination.在天花疫苗接种前后，用于评估猴痘病毒和牛痘病毒抗体的微量中和试验与多重免疫测定之间的相关性。
Front Immunol. 2025 Jun 23;16:1585284. doi: 10.3389/fimmu.2025.1585284. eCollection 2025.
9
A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus.一项系统评价，旨在确定猴痘病毒感染的新临床特征，以及对抗该病毒的治疗和预防策略。
Arch Virol. 2023 Jun 29;168(7):195. doi: 10.1007/s00705-023-05808-4.
10
An urgent need for diagnostic tools to address global mpox public health emergencies.迫切需要用于应对全球猴痘公共卫生紧急情况的诊断工具。
J Clin Microbiol. 2025 Jul 9;63(7):e0132124. doi: 10.1128/jcm.01321-24. Epub 2025 Jun 5.
引用本文的文献
1
Predictors of mpox infectious periods: findings from a fine and gray sub-distribution hazard model using Vietnamese national mpox data.猴痘感染期的预测因素：使用越南国家猴痘数据的精细灰色亚分布风险模型的研究结果
Epidemiol Infect. 2025 Aug 4;153:e89. doi: 10.1017/S0950268825100356.
2
Health insurance status and severe mpox disease outcomes among sexual minority men in NYC: a retrospective cohort study.纽约市性少数男性的健康保险状况与严重猴痘疾病结局：一项回顾性队列研究
BMC Med. 2025 Jul 9;23(1):418. doi: 10.1186/s12916-025-04252-2.
3
Clinical Predictors and Determinants of Mpox Complications in Hospitalized Patients: A Prospective Cohort Study from Burundi.住院患者猴痘并发症的临床预测因素和决定因素：来自布隆迪的一项前瞻性队列研究
Viruses. 2025 Mar 27;17(4):480. doi: 10.3390/v17040480.
4
Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials.2022年多伦多猴痘疫情期间使用特考韦瑞马的早期临床经验突出了当前临床的平衡状态以及进行随机试验的必要性。
J Antimicrob Chemother. 2025 Apr 2;80(4):935-940. doi: 10.1093/jac/dkaf010.
5
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona).临床和实验室预测指标对猴痘严重程度和持续时间的影响：一项意大利多中心队列研究（mpox-Icona）。
EBioMedicine. 2024 Sep;107:105289. doi: 10.1016/j.ebiom.2024.105289. Epub 2024 Aug 22.
6
Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City.纽约市接受长期替考韦瑞玛治疗的晚期人类免疫缺陷病毒感染者中的严重猴痘病例
Open Forum Infect Dis. 2024 May 17;11(6):ofae294. doi: 10.1093/ofid/ofae294. eCollection 2024 Jun.
7
Monkeypox Virus Neutralizing Antibodies at Six Months from Mpox Infection: Virologic Factors Associated with Poor Immunologic Response.猴痘病毒中和抗体在感染猴痘后六个月：与免疫反应不良相关的病毒学因素。
Viruses. 2024 Apr 26;16(5):681. doi: 10.3390/v16050681.
本文引用的文献
1
Mpox in people with past infection or a complete vaccination course: a global case series.既往感染或全程接种疫苗人群中的猴痘：全球病例系列研究。
Lancet Infect Dis. 2024 Jan;24(1):57-64. doi: 10.1016/S1473-3099(23)00492-9. Epub 2023 Sep 4.
2
Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study.特考韦瑞玛治疗 2022 年猴痘疫情期间的 HIV 感染者：一项回顾性队列研究。
Ann Intern Med. 2023 May;176(5):642-648. doi: 10.7326/M22-3132. Epub 2023 May 2.
3
Notes from the Field: Posttreatment Lesions After Tecovirimat Treatment for Mpox - New York City, August-September 2022.实地记录：2022年8月至9月，纽约市，痘苗病毒治疗猴痘后的治疗后病变
MMWR Morb Mortal Wkly Rep. 2023 Apr 28;72(17):471-472. doi: 10.15585/mmwr.mm7217a5.
4
Clinical characterization and placental pathology of mpox infection in hospitalized patients in the Democratic Republic of the Congo.刚果民主共和国住院患者猴痘感染的临床特征和胎盘病理学。
PLoS Negl Trop Dis. 2023 Apr 20;17(4):e0010384. doi: 10.1371/journal.pntd.0010384. eCollection 2023 Apr.
5
Mpox in people with advanced HIV infection: a global case series.晚期HIV感染者中的猴痘：一项全球病例系列研究。
Lancet. 2023 Mar 18;401(10380):939-949. doi: 10.1016/S0140-6736(23)00273-8. Epub 2023 Feb 21.
6
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022.2022 年 4 月至 6 月 16 个国家人类感染猴痘病毒。
N Engl J Med. 2022 Aug 25;387(8):679-691. doi: 10.1056/NEJMoa2207323. Epub 2022 Jul 21.
7
Clinical characteristics of human monkeypox, and risk factors for severe disease.人类猴痘的临床特征及重症疾病的危险因素。
Clin Infect Dis. 2005 Dec 15;41(12):1742-51. doi: 10.1086/498115. Epub 2005 Nov 11.
8
The Youden Index and the optimal cut-point corrected for measurement error.约登指数及针对测量误差校正的最佳切点。
Biom J. 2005 Aug;47(4):428-41. doi: 10.1002/bimj.200410133.
9
Consensus methods for medical and health services research.医学与卫生服务研究的共识方法。
BMJ. 1995 Aug 5;311(7001):376-80. doi: 10.1136/bmj.311.7001.376.
10
The nominal group as a research instrument for exploratory health studies.名义小组作为探索性健康研究的一种研究工具。
Am J Public Health. 1972 Mar;62(3):337-42. doi: 10.2105/ajph.62.3.337.
Zotero 插件